A young adult with an inherited bone marrow failure syndrome has a persistent lateral-tongue lesion. The referral needs both the mucosal findings and the syndrome history. Fanconi anaemia and dyskeratosis congenita or related telomere biology disorders can increase susceptibility to head and neck cancer. Their underlying mechanisms, associated features and surveillance plans differ. Dental students need to recognise when this history changes the threshold for coordination and follow-through.
Distinguish the two clinical contexts
Fanconi anaemia involves defects in a pathway that repairs DNA interstrand crosslinks. The clinical spectrum can include marrow failure, congenital findings and a predisposition to malignancy. Head and neck squamous cell carcinoma can occur at a younger age than expected in the general population. A patient may have undergone haematopoietic cell transplantation, which adds relevant history but does not erase their underlying predisposition.
Dyskeratosis congenita lies within a broader group of telomere biology disorders. The classic triad includes nail dystrophy, reticular skin pigmentation and oral leukoplakia, but affected people may have an incomplete or different presentation. Marrow failure, pulmonary or hepatic disease and cancer susceptibility can be relevant. A white oral lesion alone cannot establish a telomere disorder. Where the broader history raises concern, coordinate assessment with the appropriate medical and genetics teams.
| Question | Fanconi anaemia | Dyskeratosis congenita and related disorders |
|---|---|---|
| Main biological context | Impaired DNA repair | Abnormal telomere maintenance |
| Oral findings of concern | New mucosal lesion, ulcer, mass or other suspicious finding | Oral leukoplakia and new or changing focal findings |
| Useful history | Diagnosis, marrow status, transplant, GVHD, current medicines and earlier lesions | Diagnosis, prior leukoplakia, marrow and organ complications, and current surveillance |
| Key care step | Coordinate with the syndrome and head and neck teams | Coordinate with genetics, haematology and oral or head and neck specialists |
Know which plan the patient is following
Fanconi Cancer Foundation clinical guidance recommends a thorough head and neck examination every six months for people with Fanconi anaemia. The examining clinician should be familiar with the syndrome and the sites at risk. GeneReviews recommends six-monthly dental screening for dyskeratosis congenita and related telomere disorders, alongside annual cancer screening by an otolaryngologist and patient education on self-examination. These are syndrome-specific surveillance resources. Check the actual plan with the treating team, including who is responsible for each component.
A new suspicious lesion warrants assessment outside a routine interval. If the patient has missed surveillance or transferred between services, establish the last confirmed examination and the next responsible clinician. Record the part of the mouth examined and any limits. A self-examination can help a patient notice change and seek care. Professional surveillance and diagnostic assessment are separate parts of the plan.
Coordinate examination and biopsy safely
Ask about current and prior oral changes, previous dysplasia or SCC, marrow status, transplant complications and medicines. Document the exact site, dimensions, colour, firmness and progression of any lesion. Compare with earlier maps or photographs when available. If a focal red or white change, ulcer or mass is suspicious, arrange prompt specialist assessment. Send the syndrome and transplant history with the clinical description.
For invasive procedures, relevant blood counts, bleeding or infection concerns and treatment history may affect the plan. Coordinate with the treating team to arrange biopsy safely. A biopsy result should be matched to the precise area of concern, especially in a patient with longstanding leukoplakia and a new change. If the result does not explain the examination, discuss further assessment and track what is arranged.
Prepare a referral that keeps the syndrome context visible
A referral can state “confirmed Fanconi anaemia, followed by haematology,” then describe the oral finding and its time course. Include prior biopsies, transplant history where relevant and a way for the receiving service to reach the treating team through the clinical record. If the patient has a known telomere disorder, add the current surveillance plan and any previous oral leukoplakia so that a new focus can be compared with the existing map.
Ask whether the person knows which symptoms should bring them back earlier, and clarify the destination if the specialist appointment is difficult to arrange. In a teaching clinic, name the supervisor or service that will check the appointment and result. This is particularly important when a patient changes age-based services or moves between haematology and transplant follow-up. A clinical referral should remain active until its outcome is known.
Explain why the diagnosis matters to the oncology team
People with Fanconi anaemia can have increased treatment toxicity from some DNA-damaging therapies. Treatment planning requires teams familiar with the syndrome and the tumour. Other inherited marrow failure syndromes can raise different concerns related to marrow reserve or organ complications. The dentist’s role is to communicate the confirmed diagnosis, current care team and medical history promptly. Treatment choice should be tailored by the specialist team.
A new ulcer in an adult with Fanconi anaemia. Record its exact site and features and whether the patient has an established specialist pathway. Arrange prompt assessment of a suspicious ulcer and coordinate relevant medical details with haematology. Track the outcome even when the patient is due for a regular surveillance visit soon.
A new firm area within long-standing leukoplakia in a telomere disorder. Use the existing map to show where the change occurred. Send the earlier pathology and ask that the new area be assessed on its own merits. Keep the scheduled surveillance plan visible alongside the diagnostic referral.
Leave a Reply